Congruently, we confirmed the upregulation of ESSENCE after EGF treatment and down-regulation after selumetinib treatment in 2 additional CRC cell lines, DLD-1 and HT-29 (Fig. 1E). The gene discussed is EGF; the disease is colorectal carcinoma.